Aug. 20 at 3:22 PM
$DXCM delivers solid 15% revenue growth — but is it enough? 📈
With a strong boost from U.S. and international markets,
$DXCM raised its full-year revenue guidance, spotlighting the expanding type 2 non-insulin segment as a key growth driver. Yet, margin pressures and regulatory uncertainties loom, complicating the risk-reward balance.
Discover if
$DXCM's momentum can overcome near-term challenges 👉 https://www.zacks.com/stock/news/2740344/dexcom-expands-access-and-innovation-while-balancing-headwinds?cid=sm-stocktwits-2-2740344-body-8584&ADID=SYND_STOCKTWITS_TWEET_2_2740344_BODY_8584